The VCapital Management Fund allows accredited investors to participate in a number of investments, both present and future, to create a more diverse portfolio. By investing in the management fund or pool, investors are not required to meet the minimum investment for each opportunity individually.
Our investment objective is to maximize portfolio total return, principally by seeking capital gains on our equity and equity-related investments. We invest principally in the equity securities of what we believe are exceptionally high potential, emerging growth companies.
Our investment strategy is premised on a disciplined approach to identifying high potential, emerging growth companies from a range of categories broadly viewed as presenting the most fertile conditions for exceptional, profitable growth.
Our investment decisions are based on a disciplined analysis of available information regarding each potential portfolio company’s business model and growth potential. This analysis focuses on key market and industry fundamentals as well as the company’s approach to their market: target buyer attractiveness, competitive advantages, potential for recurring revenues, cost structures and projected cash flow.
An investment in the VCapital Management Co., LLC, is for preferred member interests in VCapital’s investments. These are not direct interests in specific companies, but are “profits interest.” Preferred Member Interests receive a share of profits, if any, from investments. Please see the offering documents for more information. (Note: You must have submitted your 3rd party certification in order to download the offering and subscription documents and the LLC agreement.)
What if you could inject a significantly smaller dose of toxic chemotherapy directly into a malignant tumor site and stop its growth? The potential benefits range from greatly reduced drug side effects, to a complete remission of the disease, to an inoculation against future cancer growth. For Intensity Therapeutics, these results have already been shown in mice. The company is now raising funds to advance to clinical trials, which have been fast-tracked by the U.S. Food and Drug Administration.
Intensity Therapeutics, Inc. is a biotechnology company whose mission is to greatly extend the lives of patients with solid tumor cancers. The company has partnered with the National Cancer Institute to test its pioneering new immunotherapy approach to treat cancer called in situ vaccination.
The Company’s products consist of proprietary formulations of proven chemotherapy drugs that are injected directly into tumors. Early preclinical data show that these products, when injected directly into tumors, result in significantly greater tumor growth inhibition and increased survival compared to conventionally IV-delivered chemotherapy. The technology attenuates (kills) a tumor in a manner that allows for the adaptive immune system to recognize the cancer, to attack untreated tumors, and to prevent cancer from returning.
What if the hottest venture capital deals were online, for everyone to see? If investing in highly promising businesses were not a function of who you know, but available for anyone who has the resources? VCapital is changing venture investing for the better, making more funds available in the $500k-$5 million range to promising companies with sound plans and solid management teams.
Now you have the opportunity to invest in VCapital itself. This web-based platform facilitates 24/7 access for discerning investors to learn about high-quality venture capital investment opportunities, and makes investing in these opportunities more convenient and cost efficient.
Investors in VCapital LLC will share in the firm’s 20% carried interest earnings as well as the firm’s potential exit at a substantial value. There are an estimated 8 million accredited investors in the US, yet only about 5% have ever invested in venture capital deals to date. That is about to change.
Is your smart phone or computer close to capacity with all your saved photos and videos? Imagine if you were a company like Shutterfly that stores photos for all its customers, or an entertainment site that hosts videos? In the petabyte range of data storage (one petabyte is a million gigabytes), it’s no longer feasible to have a “mirror” of everything as your backup.
Cleversafe’s breakthrough and multi-patented technology has reinvented object-based storage, addressing the need for essentially limitless data storage in a world where unstructured content in need of reliable storage continues to grow at 60-80% per year. There is an ever-increasing demand worldwide for storage of data-intensive content in everyday categories such as videos and photos, as well as for more specialized needs — genomic sequencing data, biomedical research, satellite imagery, and regulated reporting in financial services.
As the most cost-effective solution for storing huge amounts of unstructured data, Cleversafe is the market leader in private cloud storage, offering public cloud simplicity, reliability, and lower total costs.
While the company is no longer raising funds, VCapital has some limited opportunities for accredited individual investors thanks to our relationship with the founders of Batterson Venture Capital (BVC), the co-lead venture capital firm that invested in the Series A round at a $4 million value.
In 2015, after successfully introducing its product into marquee high-technology, media, government, entertainment and other organizations worldwide, Cleversafe was acquired by IBM for $1,300,000,000.
Cleversafe was one of the most successful venture capital high-tech investments in the history of Chicago venture capital investing.